Takeda Pharmaceutical Company Limited

Good day, everyone, and welcome to the conference call of Takeda Pharmaceutical Company Limited. During the presentation from the company, all the telephone lines are placed for listening mode only, and a question and answer session will be held after the presentation. Now we start the conference. Mr. O'Reilly, please go ahead.

Thank you very much for your participation in this conference call for the financial results for the third quarter of fiscal year 2020. My name is Christopher O'Reilly, Global Head of Investor Relations. Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause actual results to differ materially are discussed in our most recent Form 20F and in your other SEC filings. Please also refer to the important notice on page one of this presentation. Now, please let me introduce today's presenters and panel. Christoph Weber, President and CEO, Costa Salukas, Chief Financial Officer, Andrew Plump, President of R&D, Masato Iwasaki, President of the Japan Pharma Business Unit, Ramona Sequeira, President of the U.S. Business Unit and Global Portfolio Commercialization, and Julie Kim, President of the PDT Business Unit. First, we would like to start with a presentation followed by a question and answer session. Now, I'd like to begin.

Thank you for spending this time with us today. Well, in Q3, we are delivering on our goal and commitment in spite of the pandemic situation. which I think is demonstrating the grit of Takeda's people. If you look at our revenue, we have been accelerating our growth in Q3. And once again, I think it's a remarkable performance considering the coronavirus pandemic evolution in Q3 in many countries. This revenue growth and revenue performance is positively impacting our profitability, and you will have seen that we have a very strong profitability and very strong cooperating profit margin. Another goal that we have is to progress our pipeline, and we have seen great development. As we all know, 2021 will be a very special year when it comes to our pipeline progression, And Diplomb will come back on that. But we did share already with you very strong result with for example, or also and we filed a TAX 721 as well in the United States. So we are starting to really see momentum in our pipeline progression on our wave one progression. I will mention before having Andy developing our pipeline progression, I will mention that a few points. In 2020, we achieved carbon neutrality for the first time in our history, and that was a key commitment we had regarding our carbon emissions, so we're really, really pleased with this performance. We have been named Global Top Employer for the fourth consecutive year. We want to be an organization which provides the best people environment for our employees. We have been ranked number six in the Access to Medicine Index. As you know, this is our key commitment. We are developing life transforming medicines, but we want these life transforming medicines to reach many patients across the world, as many patients as possible across the world. And last but not least, we in December, on December 22nd, we filed our remediation report regarding our Hickory site remediations. We are very pleased that we believe that we have progressed so that we have been able to file this report and we are now awaiting answer from the FDA as the next step in term of auditing our progress. So once again, we are delivering on our goal and commitment. We are very pleased with this performance considering the environment and the headwinds that we are facing and I think it put us in very strong position to finish the fiscal year 2020. Without further ado, I will let Andy to develop our progress regarding our pipeline. Thank you very much.